Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Cullinan Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Cullinan Therapeutics, Inc.’s stock price such as:

• Cullinan Therapeutics, Inc.’s current stock price and volume
• Why Cullinan Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for CGEM from analysts
• CGEM’s stock price momentum as measured by its relative strength

About Cullinan Therapeutics, Inc. (CGEM)

Before we jump into Cullinan Therapeutics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer. It has a license agreement with Chongqing Genrix Biopharmaceutical Co., Ltd to develop and commercialize velinotamig; a co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib; and a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Want to learn more about Cullinan Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc.’s Stock Price as of Market Close

As of May 14, 2026, 10:01 AM, CST, Cullinan Therapeutics, Inc.’s stock price was $16.300.

Cullinan Therapeutics, Inc. is down 0.18% from its previous closing price of $16.330.

During the last market session, Cullinan Therapeutics, Inc.’s stock traded between $15.837 and $16.540. Currently, there are approximately 60.46 million shares outstanding for Cullinan Therapeutics, Inc..

Cullinan Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Cullinan Therapeutics, Inc. Stock Price History

Cullinan Therapeutics, Inc.’s (CGEM) price is currently up 24.9% so far this month.

During the month of May, Cullinan Therapeutics, Inc.’s stock price has reached a high of $16.540 and a low of $12.890.

Over the last year, Cullinan Therapeutics, Inc. has hit prices as high as $16.740 and as low as $5.680. Year to date, Cullinan Therapeutics, Inc.’s stock is up 57.49%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Cullinan Therapeutics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of May 13, 2026, there were 0 analysts who downgraded Cullinan Therapeutics, Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Cullinan Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Cullinan Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Cullinan Therapeutics, Inc. (CGEM) by visiting AAII Stock Evaluator.

Relative Price Strength of Cullinan Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of May 13, 2026, Cullinan Therapeutics, Inc. has a weighted four-quarter relative price strength of 18.87%, which translates to a Momentum Score of 89 and is considered to be Very Strong.

Want to learn more about how Cullinan Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Cullinan Therapeutics, Inc. Stock Price: Bottom Line

As of May 14, 2026, Cullinan Therapeutics, Inc.’s stock price is $16.300, which is down 0.18% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Cullinan Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.